Cargando…
Site-Specific Antibody Conjugation to Engineered Double Cysteine Residues
Site-specific antibody conjugations generate homogeneous antibody-drug conjugates with high therapeutic index. However, there are limited examples for producing the site-specific conjugates with a drug-to-antibody ratio (DAR) greater than two, especially using engineered cysteines. Based on availabl...
Autores principales: | Zhou, Qun, Kyazike, Josephine, Boudanova, Ekaterina, Drzyzga, Michael, Honey, Denise, Cost, Robert, Hou, Lihui, Duffieux, Francis, Brun, Marie-Priscille, Park, Anna, Qiu, Huawei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308878/ https://www.ncbi.nlm.nih.gov/pubmed/34358098 http://dx.doi.org/10.3390/ph14070672 |
Ejemplares similares
-
Engineered Fc-glycosylation switch to eliminate antibody effector function
por: Zhou, Qun, et al.
Publicado: (2020) -
Engineering an anti-CD52 antibody for enhanced deamidation stability
por: Qiu, Huawei, et al.
Publicado: (2019) -
Residue Adjacency Matrix Based Feature Engineering for Predicting Cysteine Reactivity in Proteins
por: Mapes, Norman John, et al.
Publicado: (2018) -
Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life
por: Mackness, Brian C., et al.
Publicado: (2019) -
Cysteine metabolic engineering and selective disulfide reduction produce superior antibody-drug-conjugates
por: Procopio-Melino, Renée, et al.
Publicado: (2022)